BOSTON – Mintz acted as deal counsel to Med-Pharmex, a portfolio company of private equity firm DW Healthcare Partners (DWHP), in its sale to Dechra Pharmaceuticals, a British-owned developer and manufacturer of veterinary products. California-based Med-Pharmex is a veterinary pharmaceutical manufacturer focused on developing, manufacturing and selling animal health drugs.

Through the sale, Dechra will gain further access to the U.S. veterinary health market, which Med-Pharmex has operated in for nearly 40 years, employing 130 people out of its facility in Pomona, California.

The Mintz deal team was led by Private Equity Member Gregory Fine and Associates Katya Daniel and Garrett Galvin.

Mr Fine commented: “We have worked with and supported DWHP and its portfolio companies for a number of years, and this transaction is the next step forward in its journey. Med-Pharmex was the first investment that DWHP made in the animal health market, and this deal is an example of how the right investment can help a company flourish and propel it towards a bigger future.”

Our Private Equity / Mergers & Acquisitions Practice includes 100+ professionals from many different legal areas who focus on executing transactions that meet our clients’ wide-ranging legal, business, and operational goals. Singled out by BTI Consulting Group as one of 32 “Deft Dealmaker” firms for 2022, Mintz develops winning transaction strategies for deals of virtually every size and type, including strategic acquisitions and divestitures, private equity platform and roll-up acquisitions and exits, spin-offs, joint ventures, asset and IP acquisitions, distressed sale transactions, complex earn-out and contingent value rights transactions, tender offers, and going private transactions and recapitalizations.